On Sept. 30, 2020, BD (Becton, Dickinson) announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritorﾙ Plus System had been CE marked to the IVD Directive.

The test, available in the U.S. since Jul. through an Emergency Use Authorization by the FDA, uses the BD Veritorﾙ Plus System, which is already in use across Europe to test for conditions such as Group A Strep, influenza A+B and Respiratory Syncytial Virus.